Cardiovasc Intervent Radiol (2018) 41:1008–1014 https://doi.org/10.1007/s00270-018-1940-1 CLINICAL INVESTIGATION ARTERIAL INTERVENTIONS Two-Year Clinical Outcomes of the CONSEQUENT Trial: Can Femoropopliteal Lesions be Treated with Sustainable Clinical Results that are Economically Sound? 1 2,3 4,5 6 • • • • Thomas Albrecht Matthias Waliszewski Catherine Roca Ulf Redlich 6 7 8 1 • • • • Jo ¨ rg Tautenhahn Maciej Pech Zuhir Halloul Ozlem Go ¨ gebakan 9 10 11 12 • • • • Dirk-Roelfs Meyer Ines Gemeinhardt Thomas Zeller Stefan Mu ¨ ller-Hu ¨ lsbeck 13 14 Ilka Ott Gunnar Tepe Received: 27 January 2018 / Accepted: 17 March 2018 / Published online: 27 March 2018 Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2018 Abstract events, a cost-beneﬁt analysis was conducted for the Ger- Purpose The previously reported 6-month angiographic man DRG system. and 12-month clinical outcomes of the CONSEQUENT Results There were no additional TLRs in both groups trial demonstrated the safety and efﬁcacy of a novel between 14 and 24 months so that the corresponding rates paclitaxel–resveratrol-coated balloon for the treatment of remained signiﬁcantly different between the treatment lesions in the femoropopliteal segment. The purpose
CardioVascular and Interventional Radiology – Springer Journals
Published: Mar 27, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera